
Daniella M Schwartz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3190460/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Interactions Between Autoinflammation and Type 2 Immunity: From Mechanistic Studies to Epidemiologic Associations. Frontiers in Immunology, 2022, 13, 818039.	2.2	8
2	Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific TÂcell therapy products. Molecular Therapy - Methods and Clinical Development, 2022, 25, 439-447.	1.8	4
3	Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features. Annals of the Rheumatic Diseases, 2021, 80, 788-795.	0.5	12
4	JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. Journal of Allergy and Clinical Immunology, 2021, 148, 911-925.	1.5	57
5	Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20. Annals of the Rheumatic Diseases, 2020, 79, 429-431.	0.5	25
6	Hyperlipidaemia and IFNgamma/TNFalpha Synergism are associated with cholesterol crystal formation in Endothelial cells partly through modulation of Lysosomal pH and Cholesterol homeostasis. EBioMedicine, 2020, 59, 102876.	2.7	14
7	Ca2+ Influx Channel Inhibitor SARAF Protects Mice From Acute Pancreatitis. Gastroenterology, 2019, 157, 1660-1672.e2.	0.6	33
8	Oncogenes calling on a lysosomal Ca 2+ channel. EMBO Reports, 2019, 20, .	2.0	5
9	Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology, 2019, 58, i4-i16.	0.9	111
10	STIM1 holds a STING in its (N-terminal) tail. Cell Calcium, 2019, 80, 192-193.	1.1	5
11	Retinoic Acid Receptor Alpha Represses a Th9 Transcriptional and Epigenomic Program to Reduce Allergic Pathology. Immunity, 2019, 50, 106-120.e10.	6.6	54
12	A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Annals of the Rheumatic Diseases, 2018, 77, 728-735.	0.5	176
13	Brief Report: Drugs Implicated in Systemic Autoimmunity Modulate Neutrophil Extracellular Trap Formation. Arthritis and Rheumatology, 2018, 70, 468-474.	2.9	34
14	Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. Journal of Leukocyte Biology, 2018, 104, 499-514.	1.5	122
15	Orai1-Mediated Antimicrobial Secretion from Pancreatic Acini Shapes the Gut Microbiome and Regulates Gut Innate Immunity. Cell Metabolism, 2017, 25, 635-646.	7.2	127
16	JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs, 2017, 77, 521-546.	4.9	711
17	JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery, 2017, 16, 843-862.	21.5	759
18	Targeting cytokine signaling in autoimmunity: back to the future and beyond. Current Opinion in Immunology, 2016, 43, 89-97.	2.4	47

#	Article	IF	CITATIONS
19	Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nature Reviews Rheumatology, 2016, 12, 25-36.	3.5	468
20	Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nature Genetics, 2016, 48, 67-73.	9.4	513
21	Editorial: Decernotinib: A Nextâ€Generation Jakinib. Arthritis and Rheumatology, 2016, 68, 31-34.	2.9	38
22	The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. Annual Review of Medicine, 2015, 66, 311-328.	5.0	1,074